Clinical Trials Logo

Clinical Trial Summary

A phase I clinical trial of tolerability and pharmacokinetics of TQB2858 injection in subjects with advanced malignancy.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05068921
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Beihua Kong, Doctor
Phone 18560081888
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date October 2021
Completion date July 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02853604 - Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer Phase 3
Completed NCT01088347 - Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer Phase 1/Phase 2
Recruiting NCT04590599 - A Clinical Study of Sintilimab Independently or in Combination With IBI310 (Anti-CTLA4) in Second-Line Cervical Cancer Phase 2
Recruiting NCT04731038 - Combination Therapy for First Line Treatment of Advanced Cervical Cancer Phase 1
Recruiting NCT04508686 - Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1) Phase 1
Completed NCT02888717 - Molecular Biology Analysis for Para-aortic Nodes in the Ultra-staging of Advanced Cervical Cancers N/A